Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure?
Nagai
Y
Y
Hayakawa
T
T
Abe
T
T
Nomura
G
G
D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D002316:Cardiotonic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004077:Digoxin / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007294:Inositol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male
D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007294:Inositol; D004077:Digoxin; C102817:voglibose; D020909:Acarbose